OBJECTIVE: This study was designed to investigate the long-term effects of simvastatin treatment after traumatic brain injury (TBI) in rats. METHODS: Adult female Wistar rats (n = 24) were injured with controlled cortical impact and divided into 3 groups. The first 2 groups were treated with simvastatin (0.5 or 1.0 mg/kg) administered orally for 14 days starting 1 day after TBI. The third group (control) received phosphate-buffered saline orally for 14 days. Neurological functional outcome was measured with modified neurological severity scores performed 1 day before TBI; on days 1, 4, 7, 14 after TBI; and biweekly thereafter. All animals were sacrificed 3 months after TBI. Brain tissues of half of the animals were processed for preparation of paraffin-embedded sections for immunohistological studies. The remaining half were frozen for enzyme-linked immunosorbent assay studies for quantification of brain-derived neurotrophic factor (BDNF) in the hippocampus and cortex. RESULTS: The results showed that both doses of simvastatin significantly improved functional outcome compared with the control, with no difference between the 2 doses. Simvastatin treatment of 1.0 mg/kg increased the number of morphologically intact neurons in the hippocampus, but treatment of 0.5 mg/kg had no significant effect. Enzyme-linked immunosorbent assay studies showed that 0.5 mg/kg simvastatin significantly increased BDNF levels within the hippocampus, but 1.0 mg/kg had no significant effect. Neither dose had any effect on BDNF levels within the cortex. CONCLUSION: Simvastatin treatment provides long-lasting functional improvement after TBI in rats. It also enhances neuronal survival in the hippocampus and increases BDNF levels in the hippocampus secondary to simvastatin treatment.
OBJECTIVE: This study was designed to investigate the long-term effects of simvastatin treatment after traumatic brain injury (TBI) in rats. METHODS: Adult female Wistar rats (n = 24) were injured with controlled cortical impact and divided into 3 groups. The first 2 groups were treated with simvastatin (0.5 or 1.0 mg/kg) administered orally for 14 days starting 1 day after TBI. The third group (control) received phosphate-buffered saline orally for 14 days. Neurological functional outcome was measured with modified neurological severity scores performed 1 day before TBI; on days 1, 4, 7, 14 after TBI; and biweekly thereafter. All animals were sacrificed 3 months after TBI. Brain tissues of half of the animals were processed for preparation of paraffin-embedded sections for immunohistological studies. The remaining half were frozen for enzyme-linked immunosorbent assay studies for quantification of brain-derived neurotrophic factor (BDNF) in the hippocampus and cortex. RESULTS: The results showed that both doses of simvastatin significantly improved functional outcome compared with the control, with no difference between the 2 doses. Simvastatin treatment of 1.0 mg/kg increased the number of morphologically intact neurons in the hippocampus, but treatment of 0.5 mg/kg had no significant effect. Enzyme-linked immunosorbent assay studies showed that 0.5 mg/kg simvastatin significantly increased BDNF levels within the hippocampus, but 1.0 mg/kg had no significant effect. Neither dose had any effect on BDNF levels within the cortex. CONCLUSION:Simvastatin treatment provides long-lasting functional improvement after TBI in rats. It also enhances neuronal survival in the hippocampus and increases BDNF levels in the hippocampus secondary to simvastatin treatment.
Authors: K Hoglund; K M Thelen; S Syversen; M Sjogren; K von Bergmann; A Wallin; E Vanmechelen; H Vanderstichele; D Lutjohann; K Blennow Journal: Dement Geriatr Cogn Disord Date: 2005-03-21 Impact factor: 2.959
Authors: Cole Vonder Haar; Gail D Anderson; Brandy E Elmore; Lynn H Moore; Amanda M Wright; Eric D Kantor; Fred M Farin; Theo K Bammler; James W MacDonald; Michael R Hoane Journal: J Neurotrauma Date: 2014-01-20 Impact factor: 5.269
Authors: Claudia Rita Corso; Daniel Fernandes Martins; Stephanie Carvalho Borges; Olair Carlos Beltrame; José Ederaldo Queiroz Telles; Nilza Cristina Buttow; Maria Fernanda de Paula Werner Journal: Inflammopharmacology Date: 2017-11-29 Impact factor: 4.473
Authors: Susan Margulies; Gail Anderson; Fahim Atif; Jerome Badaut; Robert Clark; Philip Empey; Maria Guseva; Michael Hoane; Jimmy Huh; Jim Pauly; Ramesh Raghupathi; Stephen Scheff; Donald Stein; Huiling Tang; Mona Hicks Journal: J Neurotrauma Date: 2015-08-06 Impact factor: 5.269
Authors: Anandakumar Shunmugavel; Mushfiquddin Khan; Peter C Te Chou; Ramanpreet K Dhindsa; Marcus M Martin; Anne G Copay; Brian R Subach; Thomas C Schuler; Mehmet Bilgen; John K Orak; Inderjit Singh Journal: J Inflamm (Lond) Date: 2010-04-19 Impact factor: 4.981
Authors: Bilal Khokhar; Linda Simoni-Wastila; Julia F Slejko; Eleanor Perfetto; Min Zhan; Gordon S Smith Journal: J Head Trauma Rehabil Date: 2018 Nov/Dec Impact factor: 2.710